Depression Scores before and after Electrocompulsive Therapy with Propofol versus Ketamine Anesthesia: A Prospective Observational Study

Noor Zuhair Alsari; Nawfal Ali Mubarak; Aqeel Ibraheem Al-Sabbagh

doi:10.54133/ajms.v9i1.2063

Authors

Noor Zuhair Alsari Al-Fayhaa Teaching Hospital, Al-Basrah, Iraq https://orcid.org/0009-0000-1135-6297
Nawfal Ali Mubarak Department of Surgery, College of Medicine, University of Basrah, Basrah, Iraq
Aqeel Ibraheem Al-Sabbagh Department of Psychiatry, College of Medicine, University of Basrah, Basrah, Iraq https://orcid.org/0000-0001-5445-4428

DOI:

https://doi.org/10.54133/ajms.v9i1.2063

Keywords:

Electrocompulsive therapy, Ketamine, Propofol, Treatment resistant depression

Abstract

Background: Major depressive disorder (MDD) is a severe condition marked by persistent sadness and functional impairment. While electrocompulsive therapy (ECT) is effective for treatment-resistant cases, the comparative effects of propofol and ketamine as anesthetic agents remain unclear. Objective: To compare the effects of propofol and ketamine anesthesia on depression severity in patients undergoing ECT using HDRS scores at multiple time points. Methods: In this prospective observational study, 50 patients with treatment-resistant depression were assigned to receive ECT with either propofol- or ketamine-based anesthesia. Depression severity was measured using HDRS at baseline and 1 week, 1 month, and 3 months post-treatment. Secondary outcomes included relapse rates and additional ECT sessions. Results: Patients receiving ketamine showed significantly greater HDRS reductions at all follow-ups (p<0.05), fewer relapses, and less need for additional ECT sessions compared with those receiving propofol. However, ketamine was associated with higher blood pressure. Conclusions: Ketamine was associated with more robust and sustained improvement in depression scores following ECT than propofol. Further studies are needed to confirm these findings and to investigate other anesthetic options.

Downloads

Download data is not yet available.

References

McIntyre RS, Alsuwaidan M, Baune BT, Berk M, Demyttenaere K, Goldberg JF, et al. Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry. 2023;22(3):394–412. doi: 10.1002/wps.21120. DOI: https://doi.org/10.1002/wps.21120

Taylor DM, Barnes TRE, Young AH, (Eds.), The Maudsley Prescribing Guidelines in Psychiatry, (14th Ed.), Hoboken: John Wiley & Sons; 2021. DOI: https://doi.org/10.1002/9781119870203

Ding Z, White PF. Anesthesia for Electroconvulsive Therapy. Anesth Analg. 2002;94(5):1351. doi: 10.1097/00000539-200205000-00057. DOI: https://doi.org/10.1097/00000539-200205000-00057

Diagnostic and statistical manual of mental disorders: DSM-5. 5th ed. Washington: American psychiatric association; 2013.

Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455(7215):894–902. doi: 10.1038/nature07455. DOI: https://doi.org/10.1038/nature07455

Cowen PJ. Cortisol, serotonin and depression: All stressed out? Br J Psychiatry. 2002;180(2):99–100. doi: 10.1192/bjp.180.2.99. DOI: https://doi.org/10.1192/bjp.180.2.99

Shirayama Y, Chen ACH, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci. 2002;22(8):3251–3261. doi: 10.1523/JNEUROSCI.22-08-03251.2002. DOI: https://doi.org/10.1523/JNEUROSCI.22-08-03251.2002

Watson S, Mackin P. HPA axis function in mood disorders. Psychiatry. 2006;5(5):166–170. doi: 10.1383/psyt.2006.5.5.166. DOI: https://doi.org/10.1383/psyt.2006.5.5.166

Rasmussen KG. Propofol for ECT anesthesia a review of the literature. J ECT. 2014;30(3):210. doi: 10.1097/YCT.0000000000000093. DOI: https://doi.org/10.1097/YCT.0000000000000093

Jankauskas V, Necyk C, Chue J, Chue P. A review of ketamine’s role in ECT and non-ECT settings. Neuropsychiatr Dis Treat. 2018;14:1437–1450. doi: 10.2147/NDT.S157233. DOI: https://doi.org/10.2147/NDT.S157233

Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression. Translational Psychiatry. [cited 2025 Jan 14]. Available from: https://www.nature.com/articles/s41398-023-02451-0

Phillips JL, Norris S, Talbot J, Birmingham M, Hatchard T, Ortiz A, et al. Single, repeated, and maintenance ketamine infusions for treatment-resistant depression: A randomized controlled trial. Am J Psychiatry. 2019;176(5):401–409. doi: 10.1176/appi.ajp.2018.18070834. DOI: https://doi.org/10.1176/appi.ajp.2018.18070834

Schwartz J, Murrough JW, Iosifescu DV. Ketamine for treatment-resistant depression: recent developments and clinical applications. Evid Based Ment Health. 2016;19(2):35–38. doi: 10.1136/eb-2016-102355. DOI: https://doi.org/10.1136/eb-2016-102355

Wang X, Chen Y, Zhou X, Liu F, Zhang T, Zhang C. Effects of propofol and ketamine as combined anesthesia for electroconvulsive therapy in patients with depressive disorder. J ECT. 2012;28(2):128–132. doi: 10.1097/YCT.0b013e31824d1d02. DOI: https://doi.org/10.1097/YCT.0b013e31824d1d02

Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–864. doi: 10.1001/archpsyc.63.8.856. DOI: https://doi.org/10.1001/archpsyc.63.8.856

Goforth HW, Holsinger T. Rapid relief of severe major depressive disorder by use of preoperative ketamine and electroconvulsive therapy. J ECT. 2007;23(1):23–25. doi: 10.1097/01.yct.0000263257.44539.23. DOI: https://doi.org/10.1097/01.yct.0000263257.44539.23